Operating Income (Loss) in USD of GUIDED THERAPEUTICS INC from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
GUIDED THERAPEUTICS INC quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • GUIDED THERAPEUTICS INC Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$485,000.000, a 13.5% increase year-over-year.
  • GUIDED THERAPEUTICS INC Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$2,195,000.000, a 6.5% decline year-over-year.
  • GUIDED THERAPEUTICS INC annual Operating Income (Loss) for 2024 was -$2,108,000.000, a 39% increase from 2023.
  • GUIDED THERAPEUTICS INC annual Operating Income (Loss) for 2023 was -$3,457,000.000, a 3.72% decline from 2022.
  • GUIDED THERAPEUTICS INC annual Operating Income (Loss) for 2022 was -$3,333,000.000, a 41.1% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

GUIDED THERAPEUTICS INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$2,195,000 -$485,000 +$76,000 +13.5% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$2,271,000 -$763,000 -$108,000 -16.5% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$2,163,000 -$414,000 -$55,000 -15.3% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$2,108,000 -$533,000 -$47,000 -9.7% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$2,061,000 -$561,000 +$62,000 +10% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$2,123,000 -$655,000 +$850,000 +56.5% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$2,973,000 -$359,000 +$484,000 +57.4% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$3,457,000 -$486,000 +$463,000 +48.8% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$3,920,000 -$623,000 +$601,000 +49.1% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$4,521,000 -$1,505,000 -$788,000 -1.1% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$3,733,000 -$843,000 -$400,000 -90.3% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q4 2022 -$3,333,000 -$949,000 -$458,000 -93.3% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$2,875,000 -$1,224,000 -$737,000 -1.5% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$2,138,000 -$717,000 -$156,000 -27.8% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$1,982,000 -$443,000 +$380,000 +46.2% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$2,362,000 -$491,000 -$203,000 -70.5% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$2,159,000 -$487,000 -$334,000 -2.2% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$1,825,000 -$561,000 -$192,000 -52% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$1,633,000 -$823,000 -$581,000 -2.4% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$1,052,000 -$288,000 -$123,000 -74.5% 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 -$929,000 -$153,000 +$35,000 +18.6% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$964,000 -$369,000 -$42,000 -12.8% 01 Apr 2020 30 Jun 2020 10-Q 18 Aug 2021
Q1 2020 -$922,000 -$242,000 +$15,000 +5.8% 01 Jan 2020 31 Mar 2020 10-Q/A 18 Aug 2021
Q4 2019 -$937,000 -$165,000 +$282,000 +63.1% 01 Oct 2019 31 Dec 2019 10-K 07 Apr 2021
Q3 2019 -$1,219,000 -$188,000 +$46,000 +19.7% 01 Jul 2019 30 Sep 2019 10-Q/A 05 Nov 2020
Q2 2019 -$1,265,000 -$327,000 +$164,000 +33.4% 01 Apr 2019 30 Jun 2019 10-Q 20 Aug 2020
Q1 2019 -$1,429,000 -$257,000 +$119,000 +31.6% 01 Jan 2019 31 Mar 2019 10-Q 07 Jul 2020
Q4 2018 -$1,548,000 -$447,000 +$288,000 +39.2% 01 Oct 2018 31 Dec 2018 10-K 20 Apr 2020
Q3 2018 -$1,836,000 -$234,000 +$1,105,000 +82.5% 01 Jul 2018 30 Sep 2018 10-Q 09 Mar 2020
Q2 2018 -$2,941,000 -$491,000 +$42,000 +7.9% 01 Apr 2018 30 Jun 2018 10-Q 11 Feb 2020
Q1 2018 -$2,983,000 -$376,000 +$138,000 +26.8% 01 Jan 2018 31 Mar 2018 10-Q 11 Jul 2019
Q4 2017 -$3,121,000 -$735,000 +$378,000 +34% 01 Oct 2017 31 Dec 2017 10-K 08 May 2019
Q3 2017 -$3,499,000 -$1,339,000 -$660,000 -97.2% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$2,839,000 -$533,000 +$365,000 +40.6% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$3,204,000 -$514,000 +$616,000 +54.5% 01 Jan 2017 31 Mar 2017 10-Q 21 May 2018
Q4 2016 -$3,820,000 -$1,113,000 +$187,000 +14.4% 01 Oct 2016 31 Dec 2016 10-K/A 20 Apr 2018
Q3 2016 -$4,007,000 -$679,000 +$1,159,000 +63.1% 01 Jul 2016 30 Sep 2016 10-Q 20 Nov 2017
Q2 2016 -$5,166,000 -$898,000 +$703,000 +43.9% 01 Apr 2016 30 Jun 2016 10-Q 18 Aug 2017
Q1 2016 -$5,869,000 -$1,130,000 +$358,000 +24.1% 01 Jan 2016 31 Mar 2016 10-Q 22 May 2017
Q4 2015 -$6,227,000 -$1,300,000 +$848,000 +39.5% 01 Oct 2015 31 Dec 2015 10-K 22 Mar 2017
Q3 2015 -$7,075,000 -$1,838,000 +$577,000 +23.9% 01 Jul 2015 30 Sep 2015 10-Q 05 Dec 2016
Q2 2015 -$7,652,000 -$1,601,000 +$426,000 +21% 01 Apr 2015 30 Jun 2015 10-Q 17 Aug 2016
Q1 2015 -$8,078,000 -$1,488,000 +$591,000 +28.4% 01 Jan 2015 31 Mar 2015 10-Q 19 May 2016
Q4 2014 -$8,669,000 -$2,148,000 -$798,000 -59.1% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016
Q3 2014 -$7,871,000 -$2,415,000 -$775,000 -47.3% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015
Q2 2014 -$7,096,000 -$2,027,000 -$286,000 -16.4% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015
Q1 2014 -$6,810,000 -$2,079,000 -$204,000 -10.9% 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015
Q4 2013 -$6,606,000 -$1,350,000 -$183,000 -15.7% 01 Oct 2013 31 Dec 2013 10-K 25 Mar 2015
Q3 2013 -$6,423,000 -$1,640,000 -$670,000 -69.1% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 -$5,753,000 -$1,741,000 -$593,000 -51.7% 01 Apr 2013 30 Jun 2013 10-Q 13 Aug 2014
Q1 2013 -$5,160,000 -$1,875,000 -$879,000 -88.3% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014
Q4 2012 -$4,281,000 -$1,167,000 +$1,715,000 +59.5% 01 Oct 2012 31 Dec 2012 10-K 26 Mar 2014
Q3 2012 -$5,996,000 -$970,000 +$1,679,000 +63.4% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013
Q2 2012 -$7,675,000 -$1,148,000 -$663,000 -1.4% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$7,012,000 -$996,000 -$256,000 -34.6% 01 Jan 2012 31 Mar 2012 10-Q 14 May 2013
Q4 2011 -$6,756,000 -$2,882,000 01 Oct 2011 31 Dec 2011 10-K 27 Mar 2013
Q3 2011 -$2,649,000 01 Jul 2011 30 Sep 2011 10-Q 13 Nov 2012
Q2 2011 -$485,000 +$46,000 +8.7% 01 Apr 2011 30 Jun 2011 10-Q/A 24 Aug 2012
Q1 2011 -$740,000 01 Jan 2011 31 Mar 2011 10-Q 14 May 2012
Q2 2010 -$531,000 01 Apr 2010 30 Jun 2010 10-Q 14 Nov 2011

GUIDED THERAPEUTICS INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2,108,000 +$1,349,000 +39% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$3,457,000 -$124,000 -3.7% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$3,333,000 -$971,000 -41.1% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$2,362,000 -$1,310,000 -1.2% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$1,052,000 -$115,000 -12.3% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022
2019 -$937,000 +$611,000 +39.5% 01 Jan 2019 31 Dec 2019 10-K 07 Apr 2021
2018 -$1,548,000 +$1,573,000 +50.4% 01 Jan 2018 31 Dec 2018 10-K 20 Apr 2020
2017 -$3,121,000 +$699,000 +18.3% 01 Jan 2017 31 Dec 2017 10-K 08 May 2019
2016 -$3,820,000 +$2,407,000 +38.7% 01 Jan 2016 31 Dec 2016 10-K/A 20 Apr 2018
2015 -$6,227,000 +$2,442,000 +28.2% 01 Jan 2015 31 Dec 2015 10-K 22 Mar 2017
2014 -$8,669,000 -$2,063,000 -31.2% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016
2013 -$6,606,000 -$2,325,000 -54.3% 01 Jan 2013 31 Dec 2013 10-K 25 Mar 2015
2012 -$4,281,000 +$2,475,000 +36.6% 01 Jan 2012 31 Dec 2012 10-K 26 Mar 2014
2011 -$6,756,000 -$5,135,000 -3.2% 01 Jan 2011 31 Dec 2011 10-K 27 Mar 2013
2010 -$1,621,000 01 Jan 2010 31 Dec 2010 10-K 28 Mar 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.